

Leveraging Small Business and Industry Assistance (SBIA) Resources


Renu Lal, PharmD, BCACP

Lieutenant Commander, U.S. Public Health Service CDER Small Business and Industry Assistance (SBIA) Division of Drug Information (DDI) Office of Communications (OCOMM) CDER | U.S. FDA


www.fda.gov

REdI Annual Conference – June 2023

Objectives



Organizational Structure



SBIA Mission

✓ Provide industry stakeholders with immediate access to resources, education & training

✓ Allow for a more clearly informed and efficient developmental process

 ✓ Align with CDER's goal of approving safe and effective human drugs and biopharmaceuticals



SBIA Audience



Resources



Direct Communications Services

- Phone: 301-796-6707 | 866-405-5367
- Email: CDERSBIA@fda.hhs.gov

(Monday – Friday 8 AM – 4:30 PM ET)

Training: Workshops and Conferences



CDER SMALL BUSINESS AND INDUSTRY ASSISTANCE ISBIA) REGULATORY BEST PRACTICES FOR GLOBAL ACCESS TO MEDICINES, INCLUDING ANTI-TB MEDICINES AUGUST 16-18



CDER SMALL BUSINESS AND INDUSTRY ASSISTANCE (SBIA)

FDA NanoDay SYMPOSIUM 2022

ive his over DEMINIA

Training: Webinars

CDER SMALL BUSINESS AND INDUSTRY ASSISTANCE WEBINARS

FDA

www.fda.gov/CDERSBIALearn



Training: SBIA Chronicles



Short electronic newsletter, highlighting a specific regulatory issue in an easy-to-read format.

Accompanied by an audio podcast

www.fda.gov/cdersbiachronicles





www.fda.gov/cdersbia

CDER Small Business & Industry Assistance (SBIA)

A Comprehensive Resource for Information on Human Drug Development in Regulation

Subscribe to Email Updates	f Share	🎔 Tweet	in Linkedin	🔛 Email	🔒 Print	
----------------------------	---------	---------	-------------	---------	---------	--

Register for Upcoming Events

Date	Time	Event	Location
June 5-9,	8:40 AM -	Regulatory Education for Industry (REdI) Annual Conference 2023	Conference
2023	4:30 PM		
May 24,	9:00 AM -	An Update on Field Alert Reports (FAR) and Biological Product Deviation	Webinar
2023	2:00 PM	Reports (BPDR)	
May 16,	1:00 PM -	OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2023	Webinar
2023	2:00 PM	User Fees and Registration	
May 15,	1:00 PM -	A Deep Dive: GDUFA III Scientific Meetings	Webinar
2023	4:30 PM		
May 2,	1:00 PM -	Navigating the First ICH Generic Drug Draft Guideline "M13A Bioequivalence	Webinar
2023	3:30 PM	for Immediate-Release Solid Oral Dosage Forms"	

www.fda.gov/cdersbia



Regulatory References

Find information on drug development, applications, submissions, manufacturing & quality, safety, labeling and more



SBIA on LinkedIn

Stay connected and receive regulatory updates and event notifications

REGULATORY REFERENCES, TRAINING, AND RESOURCES



SBIA Learn Online Training Repository

Search for conferences, webinars, online courses, newsletters and podcasts

C



SBIA Learning Library on YouTube

Browse conference and webinar recordings on YouTube

www.fda.gov/cdersbia



Regulatory References

Find information on drug development, applications, submissions, manufacturing & quality, safety, labeling and more

Search for Regulatory References | Drugs

f Share 💓 Tweet in Linkedin Email 🔒 Print

Use filter and search box to find regulatory resources Topic New Drug Review, New Drug Application (NDA) Clear Filter Se Labeling Export Excel Show 10 entries Meetings, Engaging with FDA New Drug Review, New Drug Application tacts; Investigational New Drug Application (IND); New Drug Review, New Drug (NDA) ic Drugs, Abbreviated New Drug Application (ANDA) Over-the-Counter Drug Review rug Application (NDA); Investigational New Drug Application (IND) Coronavirus Treatment Acceleration Program New Drug Review, New Drug Application (NDA); Clinical Trials, Drug Development and Approval (CTAP) Electronic Common Technical Document (eCTD) Submissions, Forms, Contacts; Investigational New Drug Application (IND); New Drug Review, New Drug Application (NDA); Generic Drugs, Abbreviated New Drug Application (ANDA) Submissions, Forms, Contacts; Investigational New Drug Application (IND); New Drug Review, New Drug FDA IND, NDA, ANDA, or Drug Master File

Application (NDA); Generic Drugs, Abbreviated New Drug Application (ANDA); Drug Master Files FDA List of Authorized Generic Drugs Generic Drugs, Abbreviated New Drug Application (ANDA); New Drug Review, New Drug Application (NDA) Formal Meetings Between the FDA and Meetings, Engaging with FDA;

Binders

Property of Applicants of PDUEA Products

Investigational New Drug Application (NDA): New Drug Paview, New Drug Application (NDA)



www.fda.gov/cdersbialearn



SBIA Learn Online Training Repository


Search for conferences, webinars, online courses, newsletters and podcasts

CDER Small Business and Industry Assistance (SBIA) Learn

Online Training Repository

Subscribe to Ernall Updates	f Shire	¥ Teret	in Loteria	🖀 Emai	🖶 Prett
-----------------------------	---------	---------	------------	--------	---------

The table below lists SBIA multimedia training resources, including conference/webinar presentations and recordings, online courses, newsletters and podcasts. Explore the SBIA recordings on YouTube to browse by most popular videos and see upcoming events for a list of future live events.







SBIA Learning Library on YouTube

Browse conference and webinar recordings on YouTube

You Tube → FDA → Playlists → CDER Small Business and Industry Assistance

CDER SBIA YouTube Learning Library

Subscribe to Email Updates 🕴 f Share 🎔 Tweet 🚺 Linkedin 🖾 Email 🔒 Print

FDA's CDER Small Business and Industry Assistance (SBIA) is making available our YouTube learning library - now hundreds of our recordings are readily accessible.

Bookmark and share 2022 2, 2021 2, 2020 2 recordings of webinar and conference presentations. New content will be posted on <u>SBLA's LinkedIn page</u> 2, and top viewed presentations will be updated quarterly. The subject matter expert presentations are intended to educate and help industry navigate FDA policies and procedures.

<u>Register</u> for upcoming CDER SBIA webinars and conferences to learn directly from FDA subject matter experts and earn free continuing education.

Most Viewed 2022 Presentations

1. FDA Clinical Investigator Training Course (CITC) 2022




- 2. FDA NanoDay Symposium 2022
- 3. DMF Workshop: GDUFA III Enhancements and Structured Data Submissions Session 3 🖸
- 4. More 2022 Recordings... 🗹





SBIA on LinkedIn

Stay connected and receive regulatory updates and event notifications





CDER Small Business and Industry Assistance (SBIA)

FDA's information and training source for the regulated pharmaceutical industry Pharmaceutical Manufacturing - Silver Spring, MD - 27,212 followers

✓ Following Learn more ♂ More				
Home About Posts	Events Videos			
FDA	All Images Videos Articles Documents Ads			
PDA	Sort by: Top 💌			
CDER Small Business and Industry Assistance (SBIA)	CDER Small Business and Industry Assistance (SBIA) *** 27.212 followers 1w • (0)			
27,212 followers	Test your knowledge! The answer will be posted once the poll closes.			
	What is the most significant difference between recommendations in M13Asee more			
	What is the most significant difference between recommendations in M13A as compared to FDA's current draft guidance on BE for ANDAs? The author can see how you vote. Learn more			
	A. (See above for options)			
	B. (See above for options)			
	C. (See above for options)			
	D. (See above for options)			

News and Updates: Email Subscriptions



Receive this emeriles a forward? Subscribe in COSPI SRIA Industry underes

EDA Small Business and Industry Assistance (SBIA)

Regulatory Education for Industry (REdI) Annual Conference

JUNE 5 - 9, 2023



Learn directly from the FDA's regulatory experts in medical product centers: drugs, devices, and biologics. This course is designed to provide participants with a strong, basic doundadog in the FDA's regulatory requirements, and also create awareness of current activities.

Plenary Session Faculty





FDA | CDER | Small Business and Industry Assistance

FDA Publishes Final Question-and-Answer Guidance on a Risk-Based Approach to Monitoring Clinical Investigations

Today, the U.S. Food and Drug Administration published a final guidance for industry, "<u>A Risk-Based</u> Approach to Monitoring of Clinical Investigations – Questions and Answers."

The purpose of the guidance is to provide industry with recommendations on implementing a risk-based approach to monitor investigational studies on human drugs, biologics, medical devices, and combinations of these products. It expands on FDA's 2013 guidance for industry "<u>Oversight of Clinical Investigations – A Risk</u>. <u>Rased Approach to Monitoring</u>" with additional recommendations to facilitate and encourage sponsors to implement risk-based monitoring. This guidance complements and does not supersede the 2013 guidance.

The new guidance focuses on FDA's recommendations for planning a monitoring approach, developing content for monitoring plans, and addressing and communicating results from monitoring. The questions and answers in this guidance strive to help sponsors plan and use risk-based approaches to monitor clinical investigations.

Revisions to the draft guidance included changes made in response to public comments that requested clarification of some of FDA's recommendations for planning and implementing risk-based approaches to monitor clinical investigations.

Sponsors must monitor their clinical investigations, but they have flexibility in how they do so. FDA believes risk-based monitoring can allow sponsors to identify and address issues that could affect processes that protect human research participants and clinical trial integrity during clinical investigations.

The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research provides guidance, education and updates for regulated industry.

Challenge Question #1

In which of the SBIA resources can you find a database of searchable FDA webpages relating to drug development?

- A. Regulatory References
- B. SBIA Learn Online Training Repository
- C. Calendar of Upcoming Events
- D. SBIA Learning Library on YouTube

Challenge Question #2

Which of the following statements is <u>NOT</u> true?

- A. You can stay connected with the latest regulatory information and offerings by subscribing to the SBIA listserv and following SBIA on LinkedIn.
- B. Industry stakeholders may call or email SBIA directly.
- C. SBIA's services are only available to companies with less than 500 employees, including affiliates.
- D. SBIA offers many free conferences, webinars and workshops on various regulatory topics.

Summary and Action Items

- Email or call SBIA with your regulatory questions
 - CDERSBIA@fda.hhs.gov | 866-405-5367 or 301-796-6707
- Bookmark <u>www.fda.gov/cdersbia</u> and <u>www.fda.gov/cdersbialearn</u>
- Browse the <u>CDER SBIA playlists</u> on FDA's YouTube channel
- Follow us on LinkedIn
- Subscribe to the <u>SBIA listserv</u>